Kusurinomadoguchi (5592) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
8 Sep, 2025Executive summary
Revenue increased 28.4% year-over-year to ¥11.19 billion, with operating profit up 43% and net income attributable to shareholders up 134%, driven by strong media and core system businesses and subsidiary-developed electronic prescription management systems.
The company benefited from a one-time special demand, contributing approximately ¥500 million in sales and ¥300 million in operating profit.
Net income surged to ¥2.034 billion, aided by the absorption of a wholly owned subsidiary and the carryforward of tax losses.
Financial highlights
Consolidated revenue: ¥11.19 billion (+28% YoY); operating profit: ¥1.953 billion (+43% YoY); EBITDA: ¥3.178 billion (+37% YoY); net income: ¥2.034 billion (+134% YoY).
Stock sales increased 23% YoY to ¥7.24 billion; shot sales rose 40% YoY to ¥3.95 billion.
Final dividend per share set at ¥27, up 19.3% from previous guidance.
Cash and equivalents at year-end were ¥2.104 billion, down from ¥14.59 billion due to changes in business scheme and working capital.
Comprehensive income was ¥2.072 billion, up from ¥874 million the previous year.
Outlook and guidance
For FY2026, targets revenue of ¥12.3 billion (+15% YoY, excluding one-time subsidy effects) and operating profit of ¥2.2 billion (+33% YoY, adjusted).
Dividend forecast for FY2026 is ¥30 per share, with a 15% payout ratio.
Latest events from Kusurinomadoguchi
- Record profit and revenue growth drive higher guidance and dividend, fueled by digital healthcare and acquisitions.5592
Q3 202613 Feb 2026 - Record profit and net income driven by recurring sales growth and capital reduction effects.5592
Q2 202614 Nov 2025 - Q1 FY2025 revenue up 22.1% YoY, but profit fell due to higher SG&A from acquisitions.5592
Q1 20258 Sep 2025 - Revenue up 28% YoY, profit growth, digital healthcare demand, and guidance maintained.5592
Q2 20258 Sep 2025 - Record Q1 revenue and profit growth with strong margins; full-year guidance unchanged.5592
Q1 20268 Sep 2025 - Record Q3 profit and revenue drive upward revision of full-year outlook and dividend.5592
Q3 20258 Sep 2025